Treatment of insomnia in depressed insomniacs: Effects on health-related quality of life, objective and self-reported sleep, and depression

William Vaughn McCall, Jill N. Blocker, Ralph D'Agostino, James Kimball, Niki Boggs, Barbara Lasater, Roger Haskett, Andrew Krystal, William M. McDonald, Peter B. Rosenquist

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.

Original languageEnglish (US)
Pages (from-to)322-329
Number of pages8
JournalJournal of Clinical Sleep Medicine
Volume6
Issue number4
StatePublished - Aug 15 2010
Externally publishedYes

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
Quality of Life
Depression
Fluoxetine
Placebos
Therapeutics
Actigraphy
Ambulatory Care Facilities
Hypnotics and Sedatives
Antidepressive Agents
Outpatients
Randomized Controlled Trials
Outcome Assessment (Health Care)
Clinical Trials
Eszopiclone

Keywords

  • Actigraphy
  • Depression
  • Eszopiclone
  • Insomnia
  • Polysomnography
  • Quality of life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Neurology
  • Clinical Neurology

Cite this

Treatment of insomnia in depressed insomniacs : Effects on health-related quality of life, objective and self-reported sleep, and depression. / McCall, William Vaughn; Blocker, Jill N.; D'Agostino, Ralph; Kimball, James; Boggs, Niki; Lasater, Barbara; Haskett, Roger; Krystal, Andrew; McDonald, William M.; Rosenquist, Peter B.

In: Journal of Clinical Sleep Medicine, Vol. 6, No. 4, 15.08.2010, p. 322-329.

Research output: Contribution to journalArticle

McCall, WV, Blocker, JN, D'Agostino, R, Kimball, J, Boggs, N, Lasater, B, Haskett, R, Krystal, A, McDonald, WM & Rosenquist, PB 2010, 'Treatment of insomnia in depressed insomniacs: Effects on health-related quality of life, objective and self-reported sleep, and depression', Journal of Clinical Sleep Medicine, vol. 6, no. 4, pp. 322-329.
McCall, William Vaughn ; Blocker, Jill N. ; D'Agostino, Ralph ; Kimball, James ; Boggs, Niki ; Lasater, Barbara ; Haskett, Roger ; Krystal, Andrew ; McDonald, William M. ; Rosenquist, Peter B. / Treatment of insomnia in depressed insomniacs : Effects on health-related quality of life, objective and self-reported sleep, and depression. In: Journal of Clinical Sleep Medicine. 2010 ; Vol. 6, No. 4. pp. 322-329.
@article{96a0119d10a945878372f052f16d800f,
title = "Treatment of insomnia in depressed insomniacs: Effects on health-related quality of life, objective and self-reported sleep, and depression",
abstract = "Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.",
keywords = "Actigraphy, Depression, Eszopiclone, Insomnia, Polysomnography, Quality of life",
author = "McCall, {William Vaughn} and Blocker, {Jill N.} and Ralph D'Agostino and James Kimball and Niki Boggs and Barbara Lasater and Roger Haskett and Andrew Krystal and McDonald, {William M.} and Rosenquist, {Peter B.}",
year = "2010",
month = "8",
day = "15",
language = "English (US)",
volume = "6",
pages = "322--329",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "4",

}

TY - JOUR

T1 - Treatment of insomnia in depressed insomniacs

T2 - Effects on health-related quality of life, objective and self-reported sleep, and depression

AU - McCall, William Vaughn

AU - Blocker, Jill N.

AU - D'Agostino, Ralph

AU - Kimball, James

AU - Boggs, Niki

AU - Lasater, Barbara

AU - Haskett, Roger

AU - Krystal, Andrew

AU - McDonald, William M.

AU - Rosenquist, Peter B.

PY - 2010/8/15

Y1 - 2010/8/15

N2 - Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.

AB - Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.

KW - Actigraphy

KW - Depression

KW - Eszopiclone

KW - Insomnia

KW - Polysomnography

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=77956289672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956289672&partnerID=8YFLogxK

M3 - Article

C2 - 20726279

AN - SCOPUS:77956289672

VL - 6

SP - 322

EP - 329

JO - Journal of Clinical Sleep Medicine

JF - Journal of Clinical Sleep Medicine

SN - 1550-9389

IS - 4

ER -